Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
RFS Pharma, LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female ≥ 18 years old with HIV-1 RNA ≥ 2,000 copies/mL and currently failing therapy.
Has M184I/V mutation in addition to 0-2 thymidine analog mutations (TAMs) at screening.
Agree to be abstinent or use two reliable forms of contraception (for females) and one form for men when participating in sexual activity that could result in pregnancy.
You may not be if
Current or recent (last 30 days of study entry) AIDS defining diseases.
Genotypic resistance testing at screening indicating K65R, L74V, Q151M mutation.
Prior exposure to lopinavir/ritonavir or amdoxovir.
Impaired hepatic function (ALT \> 5 x ULN).
Women who are pregnant or breast feeding.
Clareo Health | A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.
